Multiple sclerosis in Vest-Agder county, Norway

Acta Neurologica Scandinavica

Volumn 123, Issue 6, 2011, Pages 396-399

  Vatne, A ^a   Mygland, A ^a,b   Ljostad U ^a  

^a Sørlandet Hospital   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Borrelia antibodies; Immunomodulatory treatment; Incidence; Multiple sclerosis; Norway; Prevalence

Indexed keywords

IMMUNOMODULATING AGENT;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BORRELIA BURGDORFERI; CHILD; FEMALE; HUMAN; INCIDENCE; MALE; MULTIPLE SCLEROSIS; NORWAY; PREVALENCE;

ADULT; ANTIBODIES; BORRELIA BURGDORFERI; COMORBIDITY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYME NEUROBORRELIOSIS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NORWAY; PREVALENCE;

EID: 79954512454     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01411.x     Document Type: Article

References (19)

1. Alstadhaug KB, Olavsen J, Salvesen R. [Occurrence of multiple sclerosis in Nordland, 1970-1999]. Tidsskr Nor Laegeforen 2005;125:431-3.
2. Celius EG, Vandvik B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur J Neurol 2001;8:463-9.
3. Dahl OP, Aarseth JH, Myhr KM, Nyland H, Midgard R. Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurol Scand 2004;109:378-84.
4. Edland A, Nyland H, Riise T, Larsen JP. Epidemiology of multiple sclerosis in the county of Vestfold, eastern Norway: incidence and prevalence calculations. Acta Neurol Scand 1996;93:104-9.
5. Gronlie SA, Myrvoll E, Hansen G, Gronning M, Mellgren SI. Multiple sclerosis in North Norway, and first appearance in an indigenous population. J Neurol 2000;247:129-33.
6. Grytten N, Glad SB, Aarseth JH, Nyland H, Midgard R, Myhr KM. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology 2006;66:182-6.
7. Midgard R, Riise T, Nyland H. Epidemiologic trends in multiple sclerosis in More and Romsdal, Norway: a prevalence/incidence study in a stable population. Neurology 1991;41:887-92.
8. Torkildsen O, Grytten N, Myhr KM. Immunomodulatory treatment of multiple sclerosis in Norway. Acta Neurol Scand Suppl 2007;187:46-50.
9. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
10. Waterhouse J, Muir C, Correa P, Powell J. Cancer incidence in five continents. IARC Sci Publ 1976;3:453-9.
11. Fay MP. Approximate confidence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat Theory Methods 1999;28:2141-60.
12. Ahlgren C, Oden A, Toren K, Andersen O. Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol Scand 2009;119:313-20.
13. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-99.
14. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007;61:504-13.
15. Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis - observations from Norway. Neuroepidemiology 2008;30:140-6.
16. MSIS statistics on Lyme Borreliosis. MSIS 2009 [cited 2009 Sep 10];Available from: URL:
17. Mygland A, Skarpaas T, Ljostad U. Chronic polyneuropathy and Lyme disease. Eur J Neurol 2006;13:1213-5.
18. Coyle PK. Borrelia burgdorferi antibodies in multiple sclerosis patients. Neurology 1989;39:760-1.
19. Chmielewska-Badora J, Cisak E, Dutkiewicz J. Lyme borreliosis and multiple sclerosis: any connection? A seroepidemic study Ann Agric Environ Med 2000;7:141-3.